Oral administration of attenuated S. typhimurium carrying shRNA-expressing vectors as a cancer therapeutic

Area of Science:

• Biotechnology
• Genetics
• Cancer Research

Background:

• RNA interference (RNAi) is a powerful tool for gene silencing in research.
• RNAi holds therapeutic potential for suppressing disease-causing gene expression.
• Developing effective delivery systems for RNAi therapeutics is crucial.

Purpose of the Study:

• To investigate the potential of attenuated Salmonella typhimurium as a delivery vehicle for shRNA-expressing vectors.
• To evaluate the efficacy of bacteria-mediated RNAi in suppressing gene expression in mammalian cells both in vitro and in vivo.
• To assess the therapeutic effect of targeting bcl2 in a murine melanoma model.

Main Methods:

• Utilized attenuated Salmonella typhimurium to deliver shRNA-expressing vectors.
• Administered bacteria orally to mice with melanoma.
• Quantified gene silencing of bcl2 in murine melanoma cells.
• Monitored tumor growth and animal survival rates.

Main Results:

• Salmonella typhimurium successfully delivered shRNA-expressing vectors to mammalian cells, inducing RNAi.
• Oral administration resulted in significant bcl2 gene silencing in murine melanoma cells.
• Targeted gene silencing led to remarkably delayed tumor growth.
• Prolonged survival was observed in the treated mouse model.

Conclusions:

• Attenuated Salmonella typhimurium can serve as an effective delivery system for RNAi.
• Bacteria-mediated RNAi demonstrates potent anti-cancer effects.
• This approach offers a promising new strategy for cancer treatment.